Patent ID: 8008340

Claim:
A method for inhibiting casein kinase Iε activity in a patient comprising the administration to said patient a therapeutically effective amount of a compound of formula I, or a stereoisomer, enantiomer, racemate, tautomer or a pharmaceutically acceptable salt thereof, wherein X is H, Cl, F, Br, NO 2 , CN, OR 2 , NR 2 R 2 , HNSO 2 —C 1-3 alkyl, or NHCO—C 1-3 alkyl; Y is —S— or —O—; R 1 is 1) aryl, unsubstituted or substituted with one or more: a) C 1-5 alkoxy, b) OH, c) halogen, d) NR 2 R 2 , e) C 1-5 alkyl, unsubstituted or substituted with one or more: i) OH or ii) C 1-5 alkoxy; 2) a heterocycle, substituted or un-substituted with one or more: a) C 1-5 alkyl, substituted or un-substituted with one or more: i) OH or ii) C 1-5 alkoxy, b) C 1-5 alkoxy, c) OH, d) halogen, or e) NR 2 R 2 ; 3) C 1-5 alkyl, substituted or un-substituted with one or more of: a) C 1-5 alkyl, b) C 1-5 alkoxy, c) OH, or d) aryl, substituted or un-substituted with one or more of: i) C 1-5 alkyl, ii) C 1-5 alkoxy, iii) OH, iv) halogen, or v) NR 2 R 2 ; Z is 1) C(═O)NR 2 R 3 or 2) C(═O)R 4 ; R 2 is hydrogen or C 1-3 alkyl; R 3 is hydrogen, C 1-5 alkyl, or C 3-6 cycloalkyl; and R 4 is 1-piperidinyl, 1-pyrrolidinyl, 1-piperazinyl or 4-morpholinyl, unsubstituted or substituted with one or more of: 1) C 1-5 alkyl, 2) C 1-5 alkoxy, 3) OH, 4) halogen, or 5) NR 2 R 2 .